002900.SZ
Harbin Medisan Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 9.98
+0.81%Oct 27, 2026, 08:06 UTC
Harbin Sanlian Pharmaceutical reported revenue of RMB 623 million and a net loss of RMB 94.2949 million for the first three quarters of 2026.
Source:Oct 27, 2026, 08:06 UTC
Harbin Sanlian Pharmaceutical reported third-quarter 2026 revenue of RMB 194 million, up 16.00% year over year, and a net loss of RMB 50.101 million.
Source:Aug 7, 2026, 23:56 UTC
Chinese innovative drug and CXO stocks rebounded strongly, with the CSI Innovative Drug Industry Index rising 28.04% since June 9, 2026, and several stocks hitting daily limits on August 7, 2026.
Source: